This is the authors' abstract. We don't add key points for this paper.
Aim: Periodontal regeneration remains a clinical challenge, prompting a surge in the exploration of innovative biomaterials including stem cells, scaffolds, and growth factor–enhanced matrices. Numerous systematic reviews have investigated these materials; however, there is a lack of consolidated evidence assessing their clinical effectiveness, safety, and long-term utility. We aimed to critically evaluate and synthesize findings from systematic reviews regarding the effectiveness and safety of newer biomaterials in periodontal regeneration. Materials and Methods: This systematic review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines and was registered with International prospective register of systematic reviews (PROSPERO) (CRD42024546320). A literature search was conducted across PubMed, Scopus, and Web of Science up to January 2024. Reviews published in English within the past 10 years assessing novel biomaterials (e.g., stem cells, bioactive glass, growth factors, and hydrogels) for clinical periodontal regeneration were included. Data extraction and quality assessment (AMSTAR 2, Glenny et al . checklist) were performed by two independent reviewers. A narrative synthesis was undertaken; and where feasible, meta-analytical findings were described. Results: Out of 984 records, 10 high-relevance systematic reviews were included. These evaluated biomaterials such as nanohydroxyapatite, e-PRF, mesenchymal stem cells, bioactive glasses, and composite scaffolds. Most reviews reported significant improvements in probing depth, clinical attachment gain, and bone regeneration. Quality assessment revealed moderate-to-high quality in 60% of studies. Methodological heterogeneity, lack of protocol registration, and limited bias assessment were identified as common limitations. Conclusion: Biomaterials, particularly stem cell–based therapies, bioactive composites, and extended-release scaffolds, show promise in enhancing regeneration. However, heterogeneity in study design and outcome reporting limits definitive clinical translation. Future trials with standardized protocols and long-term follow-ups are essential. Registration: PROSPERO ID: CRD42024546320.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Molli et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: